$OXGN Recent News Herbalife tumbles on FTC probe; Plug

New Post Public Reply Private Reply Replies (0) Message Board

Jan 5, 2015 at 9:36 AM

$OXGN Recent News

Herbalife tumbles on FTC probe; Plug Power rebounds 3:30 p.m. March 12, 2014 - Sue Chang
Oxigene shares more than double on ovarian cancer treatment results 9:58 a.m. March 12, 2014 - Russ Britt
Stock futures pulled lower by China, Ukraine worries 8:23 a.m. March 12, 2014 - William L. Watts
Plug plunges, Ukraine pops and how Twitter traded the bull market 8:09 a.m. March 12, 2014 - Shawn Langlois
Oxigene shares surge after positive clinical trial 7:39 a.m. March 12, 2014 - Saumya Vaishampayan
VeriFone shares surge after earnings, outlook 4:22 p.m. March 11, 2014 - Wallace Witkowski
Oxigene soars on ovarian cancer drug results 4:05 p.m. March 11, 2014 - MarketWatch.com
Oxigene shares jump 122% to $5.37 on study result 4:00 p.m. March 11, 2014 - Wallace Witkowski
Monday’s biggest gaining and declining stocks 5:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 2:42 p.m. June 6, 2011 - Val Brickates Kennedy
Oxigene soars on Nasdaq update 8:46 a.m. June 6, 2011 - Val Brickates Kennedy
U.S. stock futures drift; Apple’s Jobs ahead 8:04 a.m. June 6, 2011 - Kate Gibson
Diet-drug makers grab sector spotlight 2:53 p.m. June 3, 2011 - Val Brickates Kennedy
Oxigene rallies 30% ahead of study presentations 11:39 a.m. June 3, 2011 - Val Brickates Kennedy

Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta 6:00 a.m. Dec. 5, 2014 - TheStreet.com
Which Chemotherapy Should OXiGENE Test Their Zybrestat+Avastin Combo Against? 11:42 a.m. Nov. 17, 2014 - Seeking Alpha
OXiGENE: Q3 Earnings And Avastin Approval, Bull Thesis Reiterated 4:20 p.m. Nov. 14, 2014 - Seeking Alpha
Oxigene: Why I Think This Risky Biotech Is A Speculative Buy 9:15 a.m. Nov. 14, 2014 - Seeking Alpha
10-Q: OXIGENE INC 10:30 a.m. Nov. 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE (OXGN) CEO Dr. Dave Chaplin on Q3 2014 Results - Earnings Call Transcript 9:27 p.m. Nov. 12, 2014 - Seeking Alpha
OXiGENE (OXGN) Q3 2014 Results - Earnings Call Webcast 4:25 p.m. Nov. 12, 2014 - Seeking Alpha
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data 5:12 a.m. Nov. 12, 2014 - TheStreet.com
Update: OXiGENE Presents Zybrestat/Avastin Data, Bull Thesis Remains Intact 5:56 a.m. Nov. 11, 2014 - Seeking Alpha
OxiGene presents Phase 2 data on fosbretabulin 12:31 p.m. Nov. 10, 2014 - Seeking Alpha
Lower Your Expectations For OXiGENE's Presentation At The November 8 International Gynecologic Cancer Society Meeting 10:15 a.m. Nov. 6, 2014 - Seeking Alpha
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta 7:28 a.m. Oct. 24, 2014 - TheStreet.com
Update: OXiGENE Initiates Clinical Trial -- Shares Rise 6:35 a.m. Sept. 18, 2014 - Seeking Alpha
Update: OXiGENE Earnings - Q2 Miss Challenges My Patience 11:48 a.m. Aug. 6, 2014 - Seeking Alpha
OXiGENE's (OXGN) CEO David Chaplin on Q2 2014 Results - Earnings Call Transcript 7:29 p.m. Aug. 5, 2014 - Seeking Alpha
OXiGENE (OXGN) Q2 2014 Results - Earnings Call Webcast 3:25 p.m. Aug. 5, 2014 - Seeking Alpha
Update: CEO Departure And Recent Capital Raise At OXiGENE Reaffirms Bull Thesis 2:00 p.m. July 28, 2014 - Seeking Alpha
10-Q: OXIGENE INC 2:44 p.m. May 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
OXiGENE's (OXGN) CEO Peter Langecker on Q1 2014 Results - Earnings Call Transcript 7:21 p.m. May 6, 2014 - Seeking Alpha
Q1 2014 O Xi Gene, Inc Earnings Conference Call (OXGN) Q1 2014 Results - Earnings Call Webcast 3:25 p.m. May 6, 2014 - Seeking Alpha

OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of Hematology Meeting 8:01 a.m. Nov. 20, 2014 - GlobeNewswire
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other Myeloid Malignancies 4:01 p.m. Nov. 17, 2014 - GlobeNewswire
OXiGENE Reports Third Quarter 2014 Financial Results 4:04 p.m. Nov. 12, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer 3:01 a.m. Nov. 10, 2014 - GlobeNewswire
OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast 8:16 a.m. Oct. 22, 2014 - GlobeNewswire
OXiGENE Announces First Patient Enrolled in Phase 1b/2 Study of Fosbretabulin Combined With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer 3:01 p.m. Oct. 7, 2014 - GlobeNewswire
OXiGENE Announces Presentation of Data From the Phase 2 GOG186I Study at the 15th Biennial Meeting of the International Gynecologic Cancer Society 3:02 p.m. Oct. 6, 2014 - GlobeNewswire
OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors 3:01 p.m. Sept. 17, 2014 - GlobeNewswire
OXiGENE Announces Presentation at the Rodman and Renshaw Conference on September 9 3:01 p.m. Aug. 26, 2014 - GlobeNewswire
OXiGENE Reports Second Quarter 2014 Financial Results 3:01 p.m. Aug. 5, 2014 - GlobeNewswire
Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies 10:55 a.m. Aug. 4, 2014 - PR Newswire - PRF
OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. July 23, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
A New Breed of Targeted Cancer Therapeutics & Stem Cell Advancements; Effective ProDrug Therapeutics Approach for GenSpera 7:29 a.m. June 20, 2014 - PR Newswire - PRF
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors 7:01 a.m. June 17, 2014 - BusinessWire - BZX
OXiGENE, Inc. Announces $16 Million At-The-Market Registered Direct Offering 8:01 a.m. May 23, 2014 - GlobeNewswire
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer 7:32 a.m. May 16, 2014 - GlobeNewswire
OXiGENE Reports First Quarter 2014 Financial Results 3:01 p.m. May 6, 2014 - GlobeNewswire
OXiGENE Announces First Quarter 2014 Earnings Conference Call and Webcast 3:31 p.m. April 22, 2014 - GlobeNewswire
Stocks Review on Top Gainers -- Research on Uranium Energy, EarthLink Holdings, Tarena Intl., and OXiGENE 7:26 a.m. April 22, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...